Company intelligence / Profile preview
Moonlight Bio
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
Overview
Moonlight Bio has developed proprietary technologies that enhance the potency of adoptive T cell therapies by introducing genetic adaptations evolved in human biology. Their lead program—a CAR T therapy targeting solid tumors—is advancing through preclinical development with support from industry grants and strategic partnerships. No clinical results have been reported yet as all programs are preclinical
- Therapeutic areas
- Oncology
- Modalities
- T cell therapies (including CAR T cells)engineered/adoptive cell therapysingle-domain antibody-based T cell therapies
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Moonlight Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Moonlight Bio.